Search research articles
Contact Us
Filters
Showing results (181-190 of 228) with videos related to
Page
of 23
Sort By:
Frontiers of Medicine
|
December 17, 2025
Plasma cell development-based prediction of prognosis and treatment response in individual multiple myeloma
Sitao Jiang, Yuan Yang, Man Yao, et al.
Oncotarget
|
April 2, 2016
E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIs
Erbao Zhang, Dandan Yin, Liang Han, et al.
Annals of Hematology
|
January 6, 2019
Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation
Wen Gao, Jie Li, Yin Wu, et al.
International Journal of Hematology
|
October 13, 2018
Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation
Wen Gao, Jie Li, Yuan Jian, et al.
Transplantation and Cellular Therapy
|
December 16, 2025
Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents
Qiling Bu, Yiwen Jiang, Jingjing Deng, et al.
Cancer Medicine
|
April 6, 2023
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
Huixing Zhou, Yuan Jian, Juan Du, et al.
Frontiers in Oncology
|
November 16, 2020
What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
Wen Gao, Juan Du, Junru Liu, et al.
Cancer Medicine
|
September 4, 2020
Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
Wen Gao, Yuan Jian, Juan Du, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
June 21, 2018
Comparison of magnetic resonance spectroscopy (MRS) with arterial spin labeling (ASL) in the differentiation between mitochondrial encephalomyopathy, lactic Acidosis, plus stroke-like episodes (MELAS) and acute ischemic stroke (AIS)
Xiaodi Li, Yuzhou Wang, Zhanhang Wang, et al.
American Journal of Clinical Oncology
|
September 21, 2017
A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma
Jian Hou, Lugui Qiu, Yaozhong Zhao, et al.
Page
of 23
Search research articles
Search
Showing results (181-190 of 228) with videos related to
Sort By:
Page
of 23
Frontiers of Medicine
|
December 17, 2025
Plasma cell development-based prediction of prognosis and treatment response in individual multiple myeloma
Sitao Jiang, Yuan Yang, Man Yao, et al.
Oncotarget
|
April 2, 2016
E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIs
Erbao Zhang, Dandan Yin, Liang Han, et al.
Annals of Hematology
|
January 6, 2019
Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation
Wen Gao, Jie Li, Yin Wu, et al.
International Journal of Hematology
|
October 13, 2018
Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation
Wen Gao, Jie Li, Yuan Jian, et al.
Transplantation and Cellular Therapy
|
December 16, 2025
Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents
Qiling Bu, Yiwen Jiang, Jingjing Deng, et al.
Cancer Medicine
|
April 6, 2023
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
Huixing Zhou, Yuan Jian, Juan Du, et al.
Frontiers in Oncology
|
November 16, 2020
What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
Wen Gao, Juan Du, Junru Liu, et al.
Cancer Medicine
|
September 4, 2020
Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
Wen Gao, Yuan Jian, Juan Du, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
June 21, 2018
Comparison of magnetic resonance spectroscopy (MRS) with arterial spin labeling (ASL) in the differentiation between mitochondrial encephalomyopathy, lactic Acidosis, plus stroke-like episodes (MELAS) and acute ischemic stroke (AIS)
Xiaodi Li, Yuzhou Wang, Zhanhang Wang, et al.
American Journal of Clinical Oncology
|
September 21, 2017
A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma
Jian Hou, Lugui Qiu, Yaozhong Zhao, et al.
Page
of 23